Welcome to our dedicated page for ASTERA LABS SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs director Jack R. Lazar reported net share sales and an equity grant. On June 4, 2026 he sold 10,000 shares of Common Stock in open-market transactions under a Rule 10b5-1 trading plan at prices between $339.5600 and $362.8405 per share, and now directly holds 85,688 shares. He also received a grant of 837 restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.
Astera Labs, Inc. director Michael E. Hurlston received an equity award of 837 shares of common stock in the form of restricted stock units (RSUs) on June 4, 2026. After this grant, he holds 92,482 shares directly, including deferred stock units and dividend equivalent units. The RSU award will vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues his service. Each RSU converts into one share of Astera Labs common stock when it vests.
BARRATT CRAIG H reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. director Craig H. Barratt received an award of 837 restricted stock units on June 4, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continuous service with the company through the vesting date. Following this grant, Barratt directly holds 6,825 shares of common stock.
Mayer Bethany reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs director Bethany Mayer received an equity award and reported trust holdings. She was granted 837 restricted stock units (RSUs) of Astera Labs, Inc. common stock on June 4, 2026 under the company’s 2024 Stock Option and Incentive Plan.
The RSU award vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continuous service. After this grant, she holds 6,236 shares directly. A separate 839 Astera Labs shares are held indirectly by The Jantzen/Mayer Family 2002 Trust, where she is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. reported the results of its 2026 Annual Stockholders Meeting held on June 4, 2026. There were 171,281,952 common shares entitled to vote, and 141,439,565 were represented in person or by proxy.
Stockholders elected all three Class II directors to serve until the 2029 annual meeting. They also ratified PricewaterhouseCoopers LLP as the independent auditor, approved on an advisory basis the compensation of named executive officers, and supported holding future advisory votes on executive pay every one year.
Astera Labs director Stefan Dyckerhoff reported a mix of stock sales and an equity grant. Entities associated with him, including a trust and a limited partnership, sold a total of 12,499 shares of Astera Labs common stock on June 3, 2026 at weighted average prices of $364.246 and $365.087 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, individual records show continued substantial direct and indirect holdings through these entities.
On June 4, 2026, Dyckerhoff also received an award of 837 restricted stock units that will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service. Following the grant, he directly holds 60,971 shares of common stock, with additional indirect holdings held through various trusts and partnerships in which he has a pecuniary interest.
ALAB filed a Rule 144 notice reporting a proposed sale of 10,000 shares of Common Stock to be sold through Nasdaq on 06/04/2026. The filing lists issued RSUs of 8,437 (05/15/2026) and 1,563 (02/15/2026). It also discloses prior open-market sales by Jack R. Lazar of 7,500 shares on 03/05/2026 for $898,471.75 and 2,500 shares on 03/16/2026 for $325,000.00.
ALAB affiliate Stefan Dyckerhoff reported proposed sales of Common Stock via Form 144 through broker Stifel Nicolaus & Company Inc. The filing lists three proposed transactions: 11,599 shares for $2,029,828 on 04/17/2026, 13,399 shares for $2,346,435 on 04/20/2026, and 12,499 shares for $2,500,174 on 05/07/2026. The securities are Common Stock on the NYSE.
ALAB notice under Form 144 reporting a proposed sale of 30,000 shares of Common Stock acquired 09/11/2020 (listed as a Private Acquisition from Issuer/Affiliate). The filing lists multiple prior dispositions by TATE 1997 LIVING TRUST in May 2026, including sales on 05/26/2026, 05/22/2026, 05/21/2026, 05/20/2026, and 05/14/2026.
The broker identified is Morgan Stanley Smith Barney LLC. The filing supplies share counts and dollar amounts for recent transactions but does not state the timing or method for the newly proposed sale beyond the Form 144 notice.
Astera Labs, Inc. President and COO Gajendra Sanjay reported pre-planned stock sales and estate-planning transfers involving the company’s common stock. An estate planning trust referred to as "Trust 1" sold a total of 400,000 shares on May 21, 2026 in a series of open-market transactions at weighted average prices in ranges from about $288.80 to $293.50 per share, executed under a Rule 10b5-1 trading plan adopted on December 2, 2025.
The filing also shows bona fide gifts totaling 452,378 shares, including a transfer of 226,189 shares of common stock to Trust 1 for no consideration as part of estate planning. After these transactions, Sanjay holds 1,209,668 shares directly, while Trust 1 holds 5,290,402 shares, and additional 615,000-share positions are reported for separate estate planning trusts labeled Trust 2 and Trust 3, for which beneficial ownership is disclaimed except for any pecuniary interest.